In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity Pharmaceuticals Inc.

www.infi.com

Latest From Infinity Pharmaceuticals Inc.

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal

The Danish dermatology specialist could be hitting the acquisition trail again soon having taken an option to buy BridgeBio's PellePharm and its skin cancer drug patidegib in a deal that could be worth $760m.

Dermatology M & A

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

The latest drug development news and highlights from our FDA Performance Tracker.  
Drug Review Biosimilars

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

The latest drug development news and highlights from our FDA Performance Tracker.  
Drug Review Biosimilars
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register